SS-31 (Elamipretide) and Vision Research
What Current Scientific Studies Show About Mitochondrial Research in Eye Health
Article Details
🕒 Estimated Reading Time: 8–10 minutes
📅 Last Reviewed: August 2026
📚 Research Category: Cellular & Mitochondrial Research
🔬 Topic: Mitochondrial Biology & Vision Research
📖 Article Type: Research Review
Introduction
SS-31, also known as elamipretide, has attracted increasing attention in vision research because of its unique ability to target mitochondria—the structures inside cells responsible for producing energy.
The retina is one of the most metabolically active tissues in the human body and depends heavily on healthy mitochondrial function. Because of this, researchers have been investigating whether therapies that support mitochondrial function could have potential applications in retinal and optic nerve diseases.
While research remains ongoing, several published studies have explored SS-31 in both laboratory models and early-stage clinical trials involving eye diseases.
What Is SS-31?
SS-31 is a small mitochondria-targeting tetrapeptide designed to localize to the inner mitochondrial membrane.
Researchers have studied SS-31 because it binds to cardiolipin, a phospholipid found within the inner mitochondrial membrane that plays an important role in mitochondrial structure and energy production.
Rather than targeting a single receptor, SS-31 is investigated for its effects on mitochondrial function and cellular energy metabolism.
➡️ Related Article: Understanding Mitochondria
Why Are Researchers Interested in Vision?
The retina requires enormous amounts of energy to function properly.
Photoreceptor cells, retinal pigment epithelial (RPE) cells, and optic nerve cells contain large numbers of mitochondria because they constantly consume energy while processing visual information.
Scientists believe that mitochondrial dysfunction may contribute to several retinal and optic nerve disorders, making mitochondrial-targeted therapies an active area of investigation.
Research Snapshot
Category Information
Compound SS-31 (Elamipretide)
Primary Research Focus Mitochondrial Function
Vision Research Areas Retina, Optic Nerve, Macular Degeneration
Research Stage Preclinical & Clinical
Scientific Interest Cellular Energy & Mitochondrial Biology
How Could Mitochondria Affect Vision?
Healthy retinal cells rely on efficient energy production.
Researchers are studying whether improving mitochondrial function may help support:
- Cellular energy production
- Retinal cell metabolism
- Protection against oxidative stress
- Normal retinal function
- Mitochondrial health
These areas remain under active scientific investigation.
What Have Animal Studies Found?
Several preclinical studies have evaluated SS-31 in animal models of age-related vision decline.
One published study reported that treatment with SS-31 preserved aspects of visual function in aged mice and appeared to reduce age-related declines in vision. Because these findings were observed in animal models, they cannot be assumed to apply to humans without further clinical research.
These results helped generate additional interest in investigating mitochondrial-targeted therapies for retinal diseases.
Human Clinical Research
Researchers have also evaluated SS-31 in people with dry age-related macular degeneration (AMD).
In the Phase 1 ReCLAIM NCGA Study, investigators primarily evaluated the safety, tolerability, and feasibility of elamipretide while also conducting exploratory analyses of visual function.
The study reported that elamipretide was generally well tolerated, and exploratory analyses suggested possible improvements in some measures of visual function, particularly under low-light conditions. Because this was an early-phase study, larger clinical trials were needed to further evaluate these observations.
What Did Later Research Show?
The Phase 2 ReCLAIM-2 trial enrolled a larger group of participants with dry age-related macular degeneration.
While the study further evaluated safety and efficacy, it did not meet its primary efficacy endpoints. Researchers continue to analyze the findings to better understand where mitochondrial-targeted therapies may have potential and which patient populations may benefit from additional investigation.
This illustrates an important aspect of scientific research: promising early findings must be confirmed in larger, well-controlled clinical studies.
Why Is This Research Still Important?
Even though later studies produced mixed results, SS-31 remains one of the most extensively studied mitochondrial-targeted peptides.
Researchers continue investigating mitochondrial dysfunction because it has been associated with numerous biological processes involving:
👁️ Retinal biology
🧠 Neurodegenerative research
❤️ Cardiovascular research
🦴 Skeletal muscle biology
⚡ Cellular energy metabolism
As our understanding of mitochondria improves, scientists continue exploring how mitochondrial-targeted therapies may contribute to future biomedical research.
Current Areas of Investigation
Researchers continue studying SS-31 in relation to:
- Retinal mitochondrial function
- Age-related macular degeneration
- Optic nerve biology
- Oxidative stress
- Cellular energy production
- Mitochondrial dysfunction
- Healthy aging research
Many of these investigations remain experimental, and additional research is needed.
What Can We Conclude Today?
Current scientific evidence suggests that SS-31 is an important investigational compound in mitochondrial research.
Published studies demonstrate:
✔ Strong biological rationale for studying mitochondrial function in retinal cells.
✔ Encouraging findings from several laboratory and early clinical investigations.
✔ Mixed results from larger clinical trials, highlighting the need for continued research.
Like many investigational therapies, scientific understanding continues to evolve as additional studies are completed.
Key Takeaways
✔ SS-31 (elamipretide) targets mitochondria rather than traditional cell receptors.
✔ Researchers are investigating SS-31 in retinal and optic nerve research because these tissues have high energy demands.
✔ Early clinical studies explored safety and possible changes in visual function.
✔ Larger clinical trials produced mixed results and did not meet all primary efficacy endpoints.
✔ Research into mitochondrial-targeted therapies for eye diseases remains active.
Continue Exploring Related Articles
➡️ SS-31: A Research Overview
Learn about the biology and mitochondrial mechanism of SS-31.
Discover how mitochondria produce cellular energy.
➡️ Understanding Cell Signaling
Learn how cells communicate through biological signaling pathways.
➡️ How Scientists Conduct Research Studies
Understand how early research progresses into larger clinical trials.
➡️ Understanding Scientific Publications
Learn how to interpret published biomedical research.
Further Reading
1. Mettu PS, Allingham MJ, Cousins SW, et al. Phase 1 Clinical Trial of Elamipretide in Dry Age-Related Macular Degeneration and Noncentral Geographic Atrophy: ReCLAIM NCGA Study. Ophthalmology Science. 2022.
2. ReCLAIM-2: A Randomized Phase II Clinical Trial Evaluating Elamipretide in Age-related Macular Degeneration, Geographic Atrophy Growth, Visual Function, and Ellipsoid Zone Preservation. Ophthalmology Science.
Educational Notice
The information presented in this article is intended solely for educational and informational purposes regarding published scientific research.
SS-31 (elamipretide) remains an investigational compound in many areas of biomedical research. The studies discussed summarize published laboratory and clinical research and should not be interpreted as evidence of established safety, effectiveness, or approved use for any specific disease or medical condition.